Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.

Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, Simmons P, Cherryholmes G, Carnahan J, William J, Spaulding B, Satnick IR, Inzunza HD, Taylor C, Cogswell J, Novotny J, Oroudjev E, Winther H.

Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):6-12. doi: 10.1097/PAI.0000000000000605.

2.

Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Lifshitz V, Priceman SJ, Li W, Cherryholmes G, Lee H, Makovski-Silverstein A, Borriello L, DeClerck YA, Yu H.

Mol Cancer Ther. 2017 Nov;16(11):2516-2527. doi: 10.1158/1535-7163.MCT-17-0379. Epub 2017 Jul 17.

3.

SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.

Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS.

Stem Cells Dev. 2017 Sep 1;26(17):1236-1246. doi: 10.1089/scd.2017.0123. Epub 2017 Jul 27.

4.

Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.

Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS.

Mol Cancer Res. 2016 Dec;14(12):1229-1242. Epub 2016 Sep 22.

5.

Current methods of epitope identification for cancer vaccine design.

Cherryholmes GA, Stanton SE, Disis ML.

Vaccine. 2015 Dec 16;33(51):7408-7414. doi: 10.1016/j.vaccine.2015.06.116. Epub 2015 Aug 1. Review.

PMID:
26238725
6.

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2015 Jun;125(6):2547. doi: 10.1172/JCI82555. Epub 2015 Jun 1. No abstract available.

7.

TLR9 is critical for glioma stem cell maintenance and targeting.

Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H.

Cancer Res. 2014 Sep 15;74(18):5218-28. doi: 10.1158/0008-5472.CAN-14-1151. Epub 2014 Jul 21.

8.

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2. Erratum in: J Clin Invest. 2015 Jun;125(6):2547. Swiderski, Piotr [Added].

9.

Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.

Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G, Jove R.

Cancer Res. 2014 Feb 15;74(4):1227-37. doi: 10.1158/0008-5472.CAN-13-0594. Epub 2013 Oct 31.

10.

Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance.

Priceman SJ, Kujawski M, Shen S, Cherryholmes GA, Lee H, Zhang C, Kruper L, Mortimer J, Jove R, Riggs AD, Yu H.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13079-84. doi: 10.1073/pnas.1311557110. Epub 2013 Jul 22.

11.

Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils.

Zhang Z, Cherryholmes G, Chang F, Rose DM, Schraufstatter I, Shively JE.

Eur J Immunol. 2009 Nov;39(11):3181-94. doi: 10.1002/eji.200939496.

12.

High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia.

Zhang Z, Cherryholmes G, Mao A, Marek C, Longmate J, Kalos M, Amand RP, Shively JE.

Exp Biol Med (Maywood). 2008 Sep;233(9):1171-80. doi: 10.3181/0712-RM-328. Epub 2008 Jun 5.

PMID:
18535166
13.

Neutrophil secondary necrosis is induced by LL-37 derived from cathelicidin.

Zhang Z, Cherryholmes G, Shively JE.

J Leukoc Biol. 2008 Sep;84(3):780-8. doi: 10.1189/jlb.0208086. Epub 2008 Jun 4.

Supplemental Content

Loading ...
Support Center